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In the United States, the use of new synthetic opioids (e.g. fentanyl and 
derivatives) has become an increasing health issue with thousands of overdose deaths 
being observed since 2013.  With the high mortality rate associated with these 
substances, postmortem analyses and interpretation of synthetic opioids has become 
extremely important.  However, due to the novelty of these compounds, the available data 
is limited and provides challenges to toxicologists.  The focus of this project was to 
examine the postmortem distribution of new synthetic opioids in blood, vitreous humor, 
and brain tissue.  New methods were developed and validated to quantify 13 synthetic 
opioids in vitreous humor and 12 synthetic opioids in brain by liquid chromatography-
mass spectrometry (LC-MSMS), achieving a limit of quantification of 0.1 ng/mL or ng/g.  
Fifty-eight authentic case samples obtained from the New York City Office of the Chief 
Medical Examiner (NYC-OCME) were analyzed to assess the distribution and 
detectability of synthetic opioids in these postmortem samples.  Of the synthetic opioids 
included in the method, six synthetic opioids (4-ANPP, acetylfentanyl, fentanyl, 
furanylfentanyl, norfentanyl, U-47700) were detected in the authentic cases. 
Concentrations for most analytes were within the 0.1 to 100 ng/mL or ng/g calibration 
range across all three matrices, with only concentrations from acetylfentanyl and U-
47700 exceeding 100 ng/mL or ng/g. Through the case analyses, vitreous humor and 
brain demonstrated to be viable alternatives to blood when performing postmortem 
analyses of synthetic opioids.  Brain exhibited a higher detectability for most analytes 
when compared to blood and vitreous humor.   
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Novel psychoactive substances (NPS) constitute newly emerging drugs in the 
market that provide significant challenges in both forensic and clinical toxicology due to 
the large rate of NPS turnover and the lack of knowledge available (Logan et al., 2017).  
Amongst these NPS include synthetic opioids which have shown to be extremely potent, 
with some being hundreds of times more potent than morphine.  These potent opioids are 
not limited to newly synthesized compounds.  Fentanyl and MT-45 are two examples of 
synthetic opioids that have existed since the 1970s, but have been reintroduced along 
with NPS in recent years (Papsun, Krywanczyk, Voce, Bundock, and Logan, 2016).  The 
illicit and improper use of these drugs has not been as epidemic as it is today.  Synthetic 
opioid related overdose deaths in the United States have exponentially risen in recent 
years, increasing from 3,105 in 2013 to approximately 20,000 in 2016 (Armenian, Vo, 
Walker, and Lynch, 2018).  Amongst the drugs that were detected included fentanyl, 
fentanyl analogs (e.g. carfentanil, furanylfentanyl, and acetylfentanyl), and other opioid 
agonists (e.g. U-47700).  However, the number of synthetic opioid deaths may be much 
larger due to the scope of fentanyl analogs and opioid agonists continuously expanding 
and being missed by traditional forensic toxicology testing (O’Donnell, Haplin, Mattson, 
Goldberger, and Gladden, 2017).   
With this large number of overdose-related deaths occurring due to the misuse of 
synthetic opioids, further postmortem (PM) analysis and research on these substances are 
becoming extremely important.  PM analysis of drugs exists as a great challenge in 
forensic toxicology as the human body is not a static entity after death.  Drug 
concentrations in PM blood and tissue compared to antemortem (AM) cannot be assumed 
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to be equal as drugs can undergo degradation and/or bioconversion within the body after 
death thus it is important to understand the stability of drugs within different tissues 
(Drummer, 2004).  Another phenomenon that occurs in some PM cases is postmortem 
redistribution (PMR), which refers to changes in drug concentration throughout an 
individual’s body after death due to passive diffusion of drugs between tissue and blood, 
typically from high to low concentrations.  The ability to undergo PMR is affected drug 
properties, such as the volume of distribution of the drug, acidic or basic characteristics, 
pKa, drug’s lipophilicity (logP), movement of the body after death, and the part of the 
body where the sample was collected.  The existence of PMR in fentanyl has been 
reported based on the relationship observed between PM concentrations of fentanyl in 
peripheral blood and liver, considering the PM interval of each case.  Concentrations 
ratios of fentanyl in peripheral blood to liver were seen to increase as the PM interval 
increased suggesting that fentanyl likely undergoes PMR in peripheral blood (Brockbals 
et al., 2018; Palamalai et al., 2013).  Butyrylfentanyl, another synthetic opioid similar in 
physiochemical properties to fentanyl, has also shown to undergo PMR (Staeheli et al., 
2016).  The synthetic opioids analyzed in this study are chemically similar in structure to 
fentanyl and butyrylfentanyl, thus are likely to exhibit similar characteristics.  However, 
the available data on the PM analysis of these synthetic opioids is scarce.   
Organs found around the body cavity, including the heart, lungs, and liver, are 
more subject to be affected by PMR, as well as decomposition which will vary 
concentrations over time.  Vitreous humor and brain tissue are known to be least affected 
by PMR due to their ability to stay intact longer and their distant position relative to the 
cavity of the body (Baniak, Campos-Baniak, Mulla, and Kalra, 2014).  This is ideal when 
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looking for an alternative matrix to examine when blood is limited in amount or not 
available.  Studies on the distribution of newer synthetic opioids among matrices have 
been limited to central organs compared to blood to examine potential presence of PMR 
(Brockbals et al., 2018; Palamalai et al., 2013) and to case studies where the 
concentrations obtained within different matrices are representative of only a limited 
number of cases and analytes (Rohrig, Miller, and Baird, 2018; Martucci, Ingle, Hunter, 
and Rodda, 2017; Dziadosz, Klintschar, and Teske, 2017; Fort, Curtis, Nichols, and 
Niblo, 2016; Coopman, Cordonnier, and Varenberg, 2007).  Further information on the 
distribution of synthetic opioids in vitreous humor and brain tissue is necessary to assist 
with interpretation and to allow these two matrices to be applicable in casework.   
Regarding analytical methodology, there are only a few known methods available 
for the detection of newer synthetic opioids in brain, and even fewer in vitreous humor 
(Sofalvi et al., 2017; Poklis et al., 2016; Poklis et al., 2015).  These methods range from 
detecting and quantifying one to seven analytes simultaneously.  Incorporating more 
synthetic opioids to a method would improve efficiency of analyses, especially due to the 
high prevalence at this time.   
This study aims to develop a new method in both vitreous humor and brain tissue 
that can simultaneously detect multiple synthetic opioids by liquid chromatography 
tandem mass spectrometry (LC-MSMS).  In addition, this study will observe the 
postmortem distribution of synthetic opioids within blood, vitreous humor, and brain 
samples, as well as analyze the detection ability of synthetic opioids among the matrices.  
Methods were developed and validated for the detection and quantification of 13 
synthetic opioids (3-methylfentanyl, 4-ANPP, 4-methoxybutyrylfentanyl, acetylfentanyl, 
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butyrylfentanyl, carfentanil, fentanyl, furanylfentanyl, isobutyrylfentanyl, norfentanyl, p-
fluorobutyrylfentanyl, U-47700, and valerylfentanyl) in vitreous humor and 12 synthetic 
opioids (3-methylfentanyl, 4-methoxybutyrylfentanyl, acetylfentanyl, butyrylfentanyl, 
carfentanil, fentanyl, furanylfentanyl, isobutyrylfentanyl, norfentanyl, p-
fluorobutyrylfentanyl, U-47700, and valerylfentanyl) in brain tissue.  The two developed 
methods in vitreous humor and brain tissue, and a previously developed method for the 
determination of synthetic opioids in blood, were applied to 58 authentic cases from the 
New York City Office of the Chief Medical Examiner (NYC-OCME) to investigate the 
postmortem distribution of these synthetic opioids. 
2. Materials and Methods 
2.1. Reagents and Supplies 
LC-MS grade methanol, LC-MS grade acetonitrile, HPLC grade deionized water, 
and formic acid were obtained from Spectrum Chemical (New Brunswick, NJ, U.S.).  
Ammonium hydroxide, glacial acetic acid, and sodium phosphate monohydrate were 
obtained from Fisher Scientific (Waltham, MA, U.S.).  HPLC grade methanol, ethyl 
acetate, and sodium phosphate dibasic were obtained from Sigma-Aldrich (St. Louis, 
MO, U.S.).   
3-methylfentanyl, 4-ANPP, 4-methoxybutyrylfentanyl, butyrylfentanyl, 
carfentanil, furanylfentanyl, isobutyrylfentanyl, MT-45, p-fluorobutyrylfentanyl, U-
47700, valerylfentanyl, and W-18 powdered standards and acetylfentanyl standards in 
methanol were obtained from Cayman Chemical Company (Ann Arbor, MI, U.S.).  
Fentanyl, fentanyl-d5, norfentanyl oxalate, and norfentanyl-d5 oxalate standards in 
methanol were obtained from Cerilliant Corporation (Round Rock, TX, U.S.).  Powdered 
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standards and liquid standards were prepared in grade methanol when preparing stock 
solutions. 
2.2. Instrumental Parameters 
LC-MSMS analysis was performed between two Agilent 1200 Infinity Series LC 
Systems attached to an Agilent 6460 Triple Quadrupole LC/MS with an electrospray ion 
source in positive mode (ESI+).  Chromatographic separation was attained using an 
Agilent InfinityLab Poroshell 120 EC18, 2.1 x 100 mm with a 2.7 μm particle size.  The 
column compartment was kept at a constant temperature of 55˚C throughout the run.  Ten 
microliters of each extracted sample was injected with a 21 min run time.  Mobile phase 
A (MPA) comprised of 0.1% formic acid in water and mobile phase B (MPB) comprised 
of 0.1% formic acid in acetonitrile.  A gradient elution was applied at a flow rate of 0.7 
mL/min, with starting conditions of 5% MPB, increased to 90% over a time span of 16 
min, and then held steady at 100% from 17 to 19 min.  MPB returned to its initial 
conditions (5%) over a time span of 2 min.   
 Data were collected from the tandem mass spectrometer in ESI+ in multiple 
reaction mode (MRM).  The parameters were obtained from the previous LC-MSMS 
confirmation of synthetic opioids in blood method that had been already optimized by the 
NYC-OCME (Table 1).  Fentanyl-d5 was used as the internal standard for all analytes 
except for norfentanyl, which used norfentanyl-d5 as its internal standard.  The source 
parameters were set as follows: 325°C gas temperature, 10 L/min gas flow, 40 psi 
nebulizer pressure, 400°C sheath gas heater, 11 L/min sheath gas flow, and 3.5 kV 
capillary voltage.  The same parameters were applied for both the vitreous humor and 
brain methods as the same compounds were being analyzed.   
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Table 1. MRM LC-MSMS method parameters for the detection of synthetic opioids and 

















Norfentanyl 4.7 233 84 45 55 17 
Acetylfentanyl 8.6 323 188 25 105 45 
4-ANPP 9.5 281 188 15 105 36 
U-47700 10.8 329 284 15 173 36 
Fentanyl 10.9 337 188 25 105 45 
Furanylfentanyl 11.6 375 188 25 105 45 
3-methylfentanyl 12.3 351 202 23 105 45 
Carfentanil 12.6 395 335 17 246 21 
Isobutyrylfentanyl 12.8 351 188 25 105 45 
Butyrylfentanyl 13.0 351 188 25 105 45 
p-Fluorobutyrylfentanyl 13.6 369 188 25 105 45 
4-methoxybutyrylfentanyl 13.7 381 188 25 105 45 
Valerylfentanyl 15.2 365 188 25 105 45 
MT-45 15.4 349 181 25 169 19 
W-18 16.5 422 111 31 175 51 
Fentanyl-d5  
(internal standard) 
10.9 342 188 25 --- --- 
Norfentanyl-d5  
(internal standard) 
4.6 238 84 17 --- --- 
2.3. Preparation of Calibrators and QCs  
Stock solutions containing 15 synthetic opioids were prepared in LC-MS grade 
methanol at concentrations of 0.01, 0.1, and 1 mg/L for both calibrators and QC samples.  
One stock solution of the internal standard containing two deuterated compounds 
(fentanyl-d5 and norfentanyl-d5) was prepared in methanol at a concentration of 1 mg/L.   
All stock solutions were prepared at the NYC-OCME laboratory by criminalists for 
casework and research use. 
The calibrators were prepared at concentrations of 0.1, 1, 5, 10, 20, 50, and 100 
ng/mL (or ng/g for brain) and three QC samples were prepared at concentrations of 0.5, 
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8, and 80 ng/mL (or ng/g).  Depending on the matrix being analyzed, the negative 
matrices used for the calibrators, blanks, and QCs differed as follows: 
- For blood batches, seven calibrators, a blank, and three QC samples were 
prepared using 0.5 mL aliquots of negative calf blood into labeled 16 x 125 mm 
glass culture tubes.   
- For vitreous humor batches, seven calibrators and a blank were prepared using 0.5 
mL aliquots of negative calf blood, and three QC samples and a blank were 
prepared using 0.5 mL negative postmortem human vitreous humor into labeled 
16 x 125 mm glass culture tubes. 
- For brain batches, seven calibrators, a blank, and three QC samples were prepared 
using 0.5 mL aliquots of negative calf brain (homogenized and diluted 1:3 w/w in 
distilled water) into labeled 16 x 125 mm glass culture tubes. 
All calibrators and QCs were spiked using the appropriate stock solutions as indicated on 
Table 2.  After the samples were spiked, the calibrators and QC samples underwent its 
corresponding specimen batch extraction procedure. 
Table 2. Calibrator and QC sample preparation guidelines 
Sample Type  Concentration 
(ng/mL or ng/g) 




Calibrator 0.1 0.01 5 
1 0.01 50 
5 0.1 25 
10 0.1 50 
20 1 10 
50 1 25 
100 1 50 
QC 0.5 0.01 25 
8 0.1 40 




2.4. Sample Preparation and Extraction 
Extractions were performed using a positive pressure manifold (SPEware 
CEREX® System 48 Processor), followed by evaporation under nitrogen with the 
SPEware CEREX® 48 Concentrator.  Homogenization of brain tissue utilized the Fisher 
Scientific Kinematica PolyTron™ PT 10-35 GT tissue blender. The Beckman Coulter 
Allegra X-15R Centrifuge and Scientific Industries Vortex Genie Z were used throughout 
the sample preparation and extraction procedures.   
2.4.a. Blood and Vitreous Humor Samples 
Prior to extraction, the case samples were removed from the freezer no more than 
a day before extraction to be defrosted and aliquoted.  The frozen vitreous humor and 
blood samples were defrosted by being placed on a lab bench at room temperature.  
Blood samples were ready to be aliquoted once brought to room temperature.  For 
vitreous humor samples, the samples were centrifuged for 10 mins at 3000 rpm at room 
temperature in order to allow for any debris or solid substances that may be present to 
accumulate at the bottom of the glass collection tube.  Following this step, the 
supernatant of the vitreous humor samples was ready to be aliquoted.   
The sample extraction procedure used was obtained from the NYC-OCME’s 
standard operating procedure (SOP) for extracting synthetic opioids from postmortem 
blood specimens by LC-MSMS.  The procedure was validated for and applied to vitreous 
humor specimens.  
Half a milliliter of the blood/vitreous humor samples were aliquoted into 16 x 
125mm glass culture tubes labeled by case number.  Twenty-five microliters of 1 mg/L of 
the internal standard solution was added to all case samples, calibrators, blank(s), and QC 
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sample tubes and vortexed for 3 s.  Two milliliters of pH 6 phosphate buffer was added to 
each tube and vortexed for 30 s.   Each sample was centrifuged for 10 min at 3000 rpm at 
room temperature, followed by solid phase extraction (SPE).  The supernatant was 
decanted onto a UCT Xcel I cartridge and driven through the column at 1-2 psi.  Each 
column was washed by the addition of 2 mL of distilled water and 2 mL of 0.1 M acetic 
acid, applying 2-4 psi of pressure following each addition.  The columns were dried for 
15 min at 60 psi.  The samples were eluted into labeled 10 mL conical tubes with 2 mL of 
ethyl acetate: ammonium hydroxide (98:2, v/v) by gravity, followed by 1-2 psi of 
pressure.  The eluted samples were dried completely under nitrogen at 40°C.  Once dry, 
the samples were reconstituted with 200 μL of a 95:5 (v/v) mobile phase mixture A 
(0.1% formic acid in HPLC grade deionized water) and B (0.1% formic acid in LC-MS 
grade acetonitrile).  The reconstituted extracts were vortexed for 3 s and centrifuged for 
10 min at 3000 rpm at room temperature.  The extracts were transferred to labeled screw 
cap vials with polymer feet inserts and capped to be followed by LC-MSMS analysis. 
If a dilution of a case specimen was necessary due to low volume or the detected 
concentration was over the upper limit of quantitation (ULOQ), negative calf blood was 
used for the dilution of blood samples and negative human vitreous humor was used for 
the dilution of vitreous humor samples. 
2.4.b. Brain Samples 
Similarly to blood and vitreous humor samples, the case brain samples were 
removed from the freezer no more than a day before extraction to be defrosted and 
aliquoted.  The frozen brain samples were defrosted by being placed in lukewarm water 
until the specimen reached approximately room temperature.  Once brought to room 
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temperature, brain specimens were ready to be weighed and homogenized.  Brain 
specimens were prepared by weighing 3 g of tissue into a specimen cup, followed by 
adding distilled water to the cup until the total weight reached 15 g (diluted 1:3 w/w).  
The samples were homogenized using the Kinematica Polytron™ PT 10-35 GT at 5,000 
rpm for approximately 20 s.   
 The sample extraction procedure for brain samples was based off the NYC-
OCME’s standard operating procedure (SOP) for extracting synthetic opioids from 
postmortem blood specimens by LC-MSMS as previously described.   A few changes 
were made in order to optimize the procedure for this specific matrix.  These changes 
were validated through the course of method validation before being applied to case 
samples. 
Half a milliliter homogenized brain samples were aliquoted into 16 x 125mm 
glass culture tubes labeled by case number.  Twenty-five microliters of 1 mg/L of the 
internal standard stock solution was added to all case samples, calibrators, blank, and QC 
sample tubes and vortexed for 3 s.  Three milliliters of pH 6 phosphate buffer was added 
to each tube and vortexed for 30 s.   Each sample was centrifuged for 15 min at 3000 rpm 
at room temperature, followed by SPE.  The supernatant was decanted onto a UCT Xcel I 
cartridge and driven through the column at 1-2 psi.  Each column was washed by the 
addition of 2 mL of distilled water, 2 mL of 0.1 M acetic acid, and 2 mL of methanol, 
applying 2-4 psi of pressure following each addition.  The columns were dried for 15 min 
at 60 psi.  The samples were eluted into labeled 10 mL conical tubes with 2 mL of ethyl 
acetate: ammonium hydroxide (98:2, v/v) by gravity, followed by 1-2 psi of pressure.  
The eluted samples were dried completely under nitrogen at 40 °C.  Once dry, the 
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samples were reconstituted with 200 μL of a 95:5 (v/v) mobile phase mixture of A:B.  
The reconstituted extracts were vortexed for 3 s and centrifuged for 10 min at 3000 rpm 
at room temperature.  The extracts were transferred to labeled screw cap vials with 
polymer feet inserts and capped to be followed by LC-MSMS analysis. 
If a dilution of a case specimen was necessary due to low volume or the detected 
concentration was over the upper limit of quantitation (ULOQ), negative calf brain was 
used for the dilution of brain samples. 
2.5. Method Validation 
Two sets of parameters were monitored as both a cross-validation (vitreous 
humor) and a full validation (brain) were performed.  Validation guidelines as outlined by 
the Scientific Working Group for Forensic Toxicology (SWGTOX, 2013) were used as a 
guide to perform these validations so these methods could be applied toward casework.  
Amongst the tested samples were fortified specimens (human and non-human) and 
previously tested postmortem samples.  For the cross-validation of the quantification of 
synthetic opioids in vitreous humor against a blood calibration curve, the following 
parameters were monitored: bias, precision, limit of quantification (LOQ), limit of 
detection (LOD), ion suppression/enhancement (matrix effect), stability, interferences 
(endogenous only), and dilution integrity.  For the full-validation of the quantification of 
synthetic opioids in brain, the following parameters were monitored: calibration curve 
linearity, carryover, bias, precision, LOQ, LOD, ion suppression/enhancement (matrix 
effect), stability, interferences (exogenous and endogenous), and dilution integrity.  The 
method used to quantify synthetic opioids in blood specimens by LC-MSMS was 
12 
 
previously validated by the forensic toxicology laboratory at the NYC-OCME thus was 
used as is.   
The following are descriptions of how each parameter was assessed: 
- Calibration curve linearity (Brain): Linearity was examined over the range of 0.1 
to 100 ng/g, prepared by using the appropriate calibrator stock solutions (see table 
2).  Five sets of calibrators were prepared and examined over the course of 5 days.  
The residuals at each concentration for each analyte were calculated to determine 
the most acceptable best-fit model (linear vs quadratic), forcing, and weighting 
(none, 1/x, 1/x2) for each analyte.  The calibration curve’s optimal parameters 
were chosen based off the variation of residuals present in each parameter, 
resulting in choosing the parameter yielding the least significant difference 
between the set of five calibration curves.  Using the chosen best-fit model, 
forcing, and weighting, the coefficient of determination (r2) of the 5 calibration 
curves were examined for values greater than 0.99 and coefficient of variation 
(CV) values less than 20% to be deemed acceptable. 
- Carryover (Brain): The possible presence of carryover was evaluated at 
concentrations at the upper limit of quantification (ULOQ), 2x ULOQ, and 5x 
ULOQ.  One blank and three additional samples spiked at 100, 200, and 500 ng/g 
using a 1 mg/L QC stock solution were prepared and analyzed with the blank 
being re-injected twice in between the concentrated samples.  If a value over the 
LOD was detected in any of the blank re-injections following a concentrated 
injection, carryover was deemed present. 
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- Bias and Precision: Intra-/inter-day bias and precision was determined by 
evaluating three levels QC samples (0.5, 8, and 80 ng/mL or ng/g) prepared in 
either negative vitreous humor or brain tissue in triplicate to be run over 5 days, 
with a new calibration curve for each day.  Bias was assessed by making sure the 
percent error did not exceed 20% at each concentration.  Precision was assessed 
by utilizing the ANOVA: Single Factor analysis approach to calculate the within-
run and between-run %CV, where concentrations were deemed acceptable if it did 
not exceed 20%. 
- Limit of Quantification (LOQ): The LOQ was tested at 0.1 ng/mL or ng/g for each 
analyte, which is the lowest calibrator concentration.  Blank matrices from three 
different vitreous humor or brain sources ran in triplicate at 0.1 ng/mL or ng/g in 
order to ensure that all detection, identification, bias, and precision criteria were 
met. 
- Limit of Detection (LOD): The LOD was tested at 0.05 ng/mL or ng/g for each 
analyte, which is half the lowest calibrator concentration.  In order for the LOD to 
be deemed acceptable, the signal to noise ratio had to be greater than 3x the noise 
level in the negative QC.  Negative matrices from three different vitreous humor 
or brain sources ran in triplicate in order to ensure acceptable identification 
criteria had been met. 
- Ion suppression/enhancement, process efficiency, and extraction efficiency: Ion 
suppression/enhancement (matrix effect) was tested alongside process efficiency, 
and extraction efficiency using 10 different sources of a negative vitreous humor 
or brain matrix.  Three sets of samples were prepared in order to evaluate matrix 
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effect, process efficiency, and extraction efficiency simultaneously.  Set 1 
consisted of 10 samples in total, five neat samples prepared at the low (0.5 ng/mL 
or ng/g) and high QC (80 ng/mL or ng/g).  Set 2 consisted of 10 samples in total, 
five different sources of a negative matrix spiked with the low and high QC and 
extracted as normal.  Set 3 consisted of 20 samples in total, 10 negative sources 
that were extracted and spiked at the low and high QC after elution.  Peak areas 
obtained from each set were compared to one another to assess each parameter.  
Peak areas from Set 2 versus Set 1 were compared to evaluate process efficiency, 
Set 3 versus Set 1 were compared to evaluate matrix effects, and Set 3 versus Set 
2 were compared to evaluate extraction efficiency.  If the mean matrix effect 
value exceeds 20%, significant matrix effect was exhibited.  In these cases, it had 
to be demonstrated that the LOD/LOQ, bias, and precision was not adversely 
affected as well to allow for the validation to pass.  Process efficiency and 
extraction efficiency did not have designated pass or fail criteria, however were 
still examined to gather more information about the extraction method. 
- Stability: The stability of the extracted samples was evaluated by re-injecting a 
QC precision study over the course of 24 h and 48 h.  Concentrations of the re-
injected samples were calculated using the calibration curve from the initial 
injection from the precision study.  The percent difference between the fresh and 
re-injected QC extracts was calculated following each run.  If the percent 




- Interferences (Brain): The presence of interferences was evaluated using a 0.5 
ng/g QC sample, spiked with high levels of common drugs of abuse (methadone, 
heroin, cocaine, and methamphetamine at 500 ng/g and THC at 100 ng/g).  If the 
QC sample exhibited concentrations within a 20% window of the expected 
concentration, the additional compounds were not considered to be interfering 
with the integration of synthetic opioids in the tested matrix. 
- Dilution integrity (Vitreous Humor): For vitreous humor, dilution integrity was 
evaluated by performing a 1:2, 1:5, and 1:10 dilution of a 150 ng/mL spiked 
sample into a blank matrix.  The integrity was evaluated by diluting the 150 
ng/mL spiked sample in triplicated with blank human vitreous humor.  All 
analytes should quantify within 20% of 150 ng/mL when multiplied by the 
dilution factor (of 2, 5, or 10).  If the passing criteria is not met, dilutions are 
unable to be performed with that analyte. 
- Dilution integrity (Brain): For brain, dilution integrity was evaluated by 
performing a 1:2 dilution of a 150 ng/g spiked sample into a blank matrix (1:3 
w/w diluted calf brain).  The integrity was evaluated by diluting the 150 ng/g 
spiked sample in triplicated with blank calf brain homogenate.  All analytes 
should quantify within 20% of 150 ng/g when multiplied by the dilution factor (of 







2.7. Identification Criteria 
In order to confirm the presence of an analyte in a sample, the following three 
criteria had to be met:  the retention time of the analyte must be within ±0.2 min of the 
average calibrator retention time, both the quantifier and qualifier product ion for each 
analyte must be present, and the ion ratio between the two product ions had to be ±20% 
of the average calibrator ion ratios. 
In order to be able to quantify an analyte, the calibration curve for each analyte 
must have a r2 value ≥0.99. Following NYC-OCME routine procedure, if the r2 value was 
not passing, up to 2 calibrators could be removed to obtain a passing r2 value.  In cases 
where the lowest or highest calibrator had to be removed, the range of quantification 
changed accordingly.  In addition, at least 2 of the 3 QCs had to be within 20% of its 
expected concentration in order to reliably quantify an analyte in a case sample.   
2.8. Authentic Sample Collection  
The NYC-OCME, Department of Forensic Toxicology, provided authentic 
postmortem blood, vitreous humor, and brain samples.  All samples were from previously 
tested 2016 cases (January to August 2016) and were stored in freezers at -25°C.  Blood 
samples were stored in either vacutainer glass collection tubes or plastic specimen cups, 
vitreous humor samples were stored in vacutainer glass collection tubes, and brain 
samples were stored in plastic specimen cups.  Cases to be retested for this project were 
chosen based on two factors: previous detection of one or more synthetic opioids in blood 
by the confirmation method used at the NYC-OCME toxicology laboratory in 2016, and 
the availability of all three matrices (blood, vitreous humor, and brain) for re-
examination.  The source of blood was noted, but was not kept consistent amongst all 
17 
 
analyzed specimens as availability differed from case to case.  The blood sample sources 
included femoral (n=42), iliac (n=2), cardiac (n=11), and subclavian (n=3).  The manner 
of death of these cases included 56 accidental deaths, 1 suicide, and 1 homicide.  Two 
cases consisted of decomposed bodies.  The two decomposed samples were included 
within all analyses except for comparing concentration ratios (due to not having femoral 
blood available).  All samples were collected by the medical examiner within 2 days of 
the individual’s death.  Synthetic opioids were not the only substances detected in a 
majority of these cases.  Most cases involved multi-drug use including other substances 
such as benzodiazepines, ethanol, cannabinoids, heroin, opiates, and other drugs not 
included in this study. 
The previous confirmation method used in 2016 consisted of gas 
chromatography-mass spectrometry (GC-MS) analysis of the following synthetic opioids 
and metabolites: 4-ANPP, acetylfentanyl, fentanyl, furanylfentanyl, norfentanyl, p-
fluorobutyrylfentanyl, and U-47700.  By using the present method, more synthetic 
opioids were tested for to see if any other analytes could be detected in addition to the 
analytes detected from the previous method.    
3. Results 
3.1. Chromatography 
The methods for each matrix were able to efficiently detect all analytes of interest 
within the range of 0.1 to 100 ng/mL (or ng/g).  Chromatograms demonstrated good 
separation, which effectively allowed detection and quantification of each analyte.  
Figures 1 through 3 show total ion chromatograms (TIC) obtained from the 80 ng/mL or 
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ng/g QC in blood, vitreous humor, and brain to visualize the separation by each matrix-










Figure 2. Total ion chromatogram (TIC) of 80 ng/mL QC in vitreous humor.  The order 
of elution observed in the TIC starting from the first eluting analyte is as follows: 
norfentanyl, acetylfentanyl, 4-ANPP, U-47700, fentanyl, furanylfentanyl, 3-
methylfentanyl, carfentanil, isobutyrylfentanyl, butyrylfentanyl, p-fluorobutyrylfentanyl, 
4-methoxybutyrylfentanyl, valerylfentanyl, MT-45, and W-18. 
Figure 1. Total ion chromatogram (TIC) of 80 ng/mL QC in blood.  The order of elution 
observed in the TIC starting from the first eluting analyte is as follows: norfentanyl, 
acetylfentanyl, 4-ANPP, U-47700, fentanyl, furanylfentanyl, 3-methylfentanyl, 
carfentanil, isobutyrylfentanyl, butyrylfentanyl, p-fluorobutyrylfentanyl, 4-
methoxybutyrylfentanyl, valerylfentanyl, MT-45, and W-18. 
 
Figure 3. Total ion chromatogram (TIC) of 80 ng/g QC in brain tissue.  The order of 
elution observed in the TIC starting from the first eluting analyte is as follows: 
norfentanyl, acetylfentanyl, 4-ANPP, U-47700, fentanyl, furanylfentanyl, 3-
methylfentanyl, carfentanil, isobutyrylfentanyl, butyrylfentanyl, p-fluorobutyrylfentanyl, 
4-methoxybutyrylfentanyl, valerylfentanyl, and MT-45. 
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3.2. Method Validation 
The method in blood was previously validated by the NYC-OCME to quantify 13 
of the 15 synthetic opioids in question.  These 13 synthetic opioids included 3-
methylfentanyl, 4-ANPP, 4-methoxybutyrylfentanyl, acetylfentanyl, butyrylfentanyl, 
carfentanil, fentanyl, furanylfentanyl, isobutyrylfentanyl, norfentanyl, p-
fluorobutyrylfentanyl, U-47700, and valerylfentanyl.  MT-45 and W-18 were seen as 
qualitative only.  The method in vitreous humor had similar results where the same 13 of 
the 15 synthetic opioids were validated for quantitative analysis, and the remaining two 
were seen as qualitative only.  However, the method in brain differed in results where 12 
of the 15 synthetic opioids were validated for quantitative analysis.  These synthetic 
opioids included 3-methylfentanyl, 4-methoxybutyrylfentanyl, acetylfentanyl, 
butyrylfentanyl, carfentanil, fentanyl, furanylfentanyl, isobutyrylfentanyl, norfentanyl, p-
fluorobutyrylfentanyl, U-47700, and valerylfentanyl.  4-ANPP and MT-45 were seen as 
qualitative only and W-18 could not be reliably detected.  The remaining results obtained 
from the method validation have been summarized for each matrix in following sections. 
3.2.a. Vitreous Humor 
All quantitative analytes showed acceptable precision and bias with %CV less 
than 20% at the LOQ of 0.1 ng/mL (see Table 3).  The LOD was tested at 0.05 ng/mL 
and 0.1 ng/mL for all analytes.  All analytes showed acceptable signal to noise ratios and 






Table 3. Summary of precision and bias results at the LOQ (0.1 ng/mL) for each analyte 





3-methylfentanyl 3.7 2.4 18.0 
4-ANPP 5.9 2.8 1.7 
4-methoxybutyrylfentanyl 3.9 4.3 10.7 
Acetylfentanyl 1.4 0.6 1.8 
Butyrylfentanyl 3.4 2.2 4.4 
Carfentanil 3.6 1.7 6.6 
Fentanyl 3.3 3.6 6.5 
Furanylfentanyl 3.2 1.5 8.6 
Isobutyrylfentanyl 3.6 3.8 3.9 
Norfentanyl 1.3 3.0 -5.1 
p-Fluorobutyrylfentanyl 3.8 1.8 8.5 
U-47700 2.1 1.3 18.3 
Valerylfentanyl 7.0 3.3 12.8 
 
Quantitative analytes showed acceptable bias and precision at all three levels of 
QC (0.5, 8, and 80 ng/mL) in vitreous humor.  The %CV did not exceed 20% and 
the %bias was within +/-20% and thus deemed acceptable for all tested analytes, Table 4 
and 5. 
Table 4. Summary of precision results at all three levels of QC (0.5, 8, and 80 ng/mL) for 
quantitative analytes in vitreous humor (n=5) 
Analyte 













3-methylfentanyl 4.3 1.8 1.4 1.3 2.4 1.5 
4-ANPP 2.5 1.0 7.8 3.5 4.6 10.5 
4-methoxybutyrylfentanyl 3.0 3.8 6.8 2.9 4.2 3.6 
Acetylfentanyl 1.4 0.6 2.5 1.0 2.0 1.6 
Butyrylfentanyl 1.7 2.9 4.1 1.9 2.1 1.8 
Carfentanil 2.1 0.9 1.7 0.7 2.2 1.4 
Fentanyl 1.6 1.3 1.2 0.8 0.9 0.5 
Furanylfentanyl 1.5 0.6 2.8 1.2 2.1 2.7 
Isobutyrylfentanyl 2.2 2.0 3.2 1.8 2.2 1.6 
Norfentanyl 1.2 3.7 1.8 3.5 0.8 2.0 
p-Fluorobutyrylfentanyl 2.2 0.9 5.0 2.0 3.3 7.4 
U-47700 1.9 3.8 2.5 4.7 2.4 5.1 




Table 5. Summary of bias results at all three levels of QC (0.5, 8, and 80 ng/mL) for 
quantitative analytes in vitreous humor (n=5) 
Analyte 
Low QC Mid QC High QC 
%Bias %Bias %Bias 
3-methylfentanyl -1.2 -5.8 2.8 
4-ANPP 2.1 2.6 -3.3 
4-methoxybutyrylfentanyl -1.7 -2.0 -0.5 
Acetylfentanyl -0.9 -1.0 0.5 
Butyrylfentanyl -0.3 0.6 -1.9 
Carfentanil 3.8 3.8 -0.8 
Fentanyl -1.5 -1.9 0.2 
Furanylfentanyl 1.0 0.2 3.0 
Isobutyrylfentanyl -1.1 0.8 2.1 
Norfentanyl -2.9 -1.0 -7.2 
p-Fluorobutyrylfentanyl -1.0 -0.5 -0.7 
U-47700 15.9 13.2 15.4 
Valerylfentanyl -3.0 -2.1 -2.3 
Significant matrix effects (exceeding 20%) were exhibited in MT-45, p-
fluorobutyrylfentanyl, valerylfentanyl, W-18, and norfentanyl-d5 at the low QC and MT-
45 and W-18 at the high QC (refer to Table 6).  The %CV for all the analytes were below 
the 20% threshold, with the exception of valerylfentanyl at the low QC and MT-45 at 
both the low and high QC.  Although the cut-off criteria of 20% for matrix effect 
and %CV was not met for all the analytes, this did not have an impact on other critical 
validation parameters observed (LOD, LOQ, bias, precision) thus these observed matrix 
effects were considered to be not disruptive towards the qualitative/quantitative analysis 
of synthetic opioids in vitreous humor. In addition, since MT-45 was monitored by 
qualitative analysis only, it was not affected by the high %CV.  All analytes demonstrated 
optimal extraction efficiencies (>50%) ranging from 65.6% to 84.1%, except for 
norfentanyl and norfentanyl-d5 which had extraction efficiencies ranging from 29.5 to 
31.7%.  However, this did not have an effect on other critical validation parameters 
observed thus the low extraction efficiencies were not considered disruptive.   
22 
 
Table 6. Summary of matrix effect results from each analyte at the low QC (0.5 ng/mL) 
and high QC (80 ng/mL) in vitreous humor samples (n=10) 
Analyte 
Low QC High QC 
Matrix Effect %CV Matrix Effect %CV 
3-methylfentanyl -9.6 8.5 -7.5 2.4 
4-ANPP 12.2 11.9 -2.1 3.3 
4-methoxybutyrylfentanyl -23.6 17.7 -12.3 7.1 
Acetylfentanyl -5.4 4.3 -4.8 1.1 
Butyrylfentanyl 11.7 14.7 -7.6 4.3 
Carfentanil -11.1 5.8 -5.6 1.5 
Fentanyl -10.5 7.4 -5.8 2.1 
Furanylfentanyl -15.5 9.0 -7.8 2.9 
Isobutyrylfentanyl -17.6 11.4 -13.1 4.3 
MT-45 -60.4 68.2 -33.6 30.4 
Norfentanyl -19.9 8.9 -14.9 11.1 
p-Fluorobutyrylfentanyl -26.1 16.4 -15.8 6.4 
U-47700 -6.1 7.6 -7.0 2.1 
Valerylfentanyl -34.0 27.0 -16.9 12.6 
W-18 -53.8 16.2 -47.0 15.9 
Fentanyl-d5 -18.2 5.9 -8.8 1.8 
Norfentanyl-d5 -20.9 9.3 -16.8 15.2 
 All analytes had comparable results between the fresh QC and the autosampler 
stability study, with the exception of MT-45 and W-18.  MT-45 exhibited deterioration in 
the injected samples with a percent difference of 48% at the low QC after 24 h. W-18 
exhibited enhancement with a percent difference ranging from 67% to 90% at both the 
low and high QC after 24 h at room temperature.  According to this data, if extracts are 
≥24 h old at room temperature, they cannot be re-injected and expected to give accurate 
results for MT-45 and W-18.  These samples would need to be re-extracted.  However, 
for the remainder of the analytes, samples ≤48 h in the autosampler at room temperature 
can be re-injected and expected to give consistent results as compared to fresh extracts 
for all of the analytes in the method. 
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The presence of potential endogenous interferences was tested by using six 
different sources of vitreous humor.  Each source consisted of different vitreous humor 
mixtures consisting of 2 to 5 samples from previously negative tested casework. All six 
sources were negative for all analytes thus no endogenous interferences were observed.  
Isobutyrylfentanyl and butyrylfentanyl have a known interference of 3-methylfentanyl in 
LC-MSMS assays due to sharing a qualifier ion transition (351105) with one another.  
This interference was identified during the method validation of the blood method 
performed by the NYC-OCME.  However, this does not affect the quantitation of these 
analytes due to differing retention times thus they can still be analyzed together. 
 For all quantitative analytes, dilutions down to 1:10 have been proven to give 
accurate results with percent differences of -13.3% to 5.3% when compared to the 
original concentration (150 ng/mL).  MT-45 and W-18 had percent differences of -49.9% 
and 26.4% respectively, which were larger than the 20% cut-off criteria.  However, due 
to these analytes being tested qualitatively only, dilutions were not necessary. 
3.2.b. Brain Tissue 
 The chosen best-fit model and appropriate parameters for all analytes were over 
the linear range of 0.1 to 100 ng/g, non-forced, with a 1/x2 weighting applied.  The 
exception to this model was butyrylfentanyl, which incorporated forcing into its 
calibration curve model.  The parameters observed to determine the best-fit model are 
summarized in Table 7.  The r2 values for 4-ANPP and MT-45 were far below 0.99 when 
using the most acceptable best-fit model as determined by the residuals, thus did not 
uphold the validation requirements.  The average r2 value for 4-methoxybutyrylfentanyl 
and valerylfentanyl were below the required 0.99 threshold.  However, due to having 4 of 
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the 5 calibration curves above the 0.99 limit, acceptable residuals, and fulfilling the other 
validation parameters with passable results (bias, precision, LOD/LOQ), the calibration 
curves were still deemed capable of efficiently quantifying its corresponding analytes in 
samples.  Optimal calibration curves for 4-ANPP and MT-45 were unable to be 
established using the current method and thus were continued to be considered as 
qualitative only. 
Table 7. Linearity parameters of the best-fit model for each synthetic opioid and 














3-methylfentanyl 32.051 0.0200 -548.669 0.000001 0.286 0.9938 
4-methoxybutyrylfentanyl 39.447 0.5075 -145.940 -0.000063 1.148 0.9887 
Acetylfentanyl 30.630 0.6023 -260.274 -0.000023 0.038 0.9993 
Butyrylfentanyl 22.595 1.6691 --- --- 0.220 0.9968 
Carfentanil 42.209 0.4489 -237.566 -0.000049 0.094 0.9977 
Fentanyl 32.727 0.6333 -228.198 -0.000034 0.032 0.9995 
Furanylfentanyl 95.422 0.6892 1679.353 0.000015 0.254 0.9961 
Isobutyrylfentanyl 32.002 1.0461 -129.329 -0.000096 0.177 0.9977 
Norfentanyl 3.205 4.7522 60.351 0.000815 0.413 0.9937 
p-Fluorobutyrylfentanyl 31.083 1.0644 -113.502 0.000141 0.404 0.9956 
U-47700 42.830 0.6267 -215.850 -0.000046 0.275 0.9976 
Valerylfentanyl 37.368 0.4491 -823.648 -0.000013 1.396 0.9857 
All quantitative analytes showed acceptable precision and bias at the LOQ, except 
for valerylfentanyl (see Table 8).  However, due to a single outlier from the third 
repetition, the LOQ at 0.1 ng/g was deemed still passable for valerylfentanyl even with a 






Table 8. Summary of precision and bias results at the LOQ (0.1 ng/g) for each analyte in 





3-methylfentanyl 13.0 10.0 4.6 
4-methoxybutyrylfentanyl 15.8 9.4 -7.1 
Acetylfentanyl 5.1 2.4 4.4 
Butyrylfentanyl 12.9 7.3 -6.2 
Carfentanil 7.8 3.7 10.2 
Fentanyl 4.7 3.5 1.2 
Furanylfentanyl 9.3 4.4 -7.7 
Isobutyrylfentanyl 11.8 7.0 -4.2 
Norfentanyl 3.2 8.1 -11.8 
p-Fluorobutyrylfentanyl 14.0 6.6 -8.4 
U-47700 5.2 12.3 15.7 
Valerylfentanyl 29.2 13.8 -12.0 
All quantitative analytes showed acceptable signal to noise ratios greater than 1:3 
and ion ratio accuracies at 0.05 ng/g, with the exception of 3-methylfentanyl, norfentanyl, 
and isobutyrylfentanyl.  The chromatography was acceptable for isobutyrylfentanyl at 
0.05 ng/g and was clearly distinguishable therefore 0.05 ng/g was deemed passable as the 
LOD for this analyte.  For 3-methylfentanyl and norfentanyl, the chromatography was 
indistinguishable at 0.05 ng/g thus the LOD was set at 0.10 ng/g for these two analytes.  
The LOD for the qualitative analytes, 4-ANPP and MT-45, were found to be 
distinguishable at 0.05 ng/g and 5 ng/mL respectively. 
All quantitative analytes showed acceptable bias and precision for all levels of QC 
(0.5, 8, and 80 ng/g) in brain.  The %CV could not exceed 20% and the %bias had to be 
within +/-20% to be deemed acceptable, and this was observed in all the analytes as seen 





Table 9. Summary of precision results at all three levels of QC (0.5, 8, and 80 ng/g) for 
quantitative analytes in brain (n=5) 
Analyte 













3-methylfentanyl 2.8 2.6 2.5 1.5 2.4 1.6 
4-methoxybutyrylfentanyl 6.3 4.0 5.1 2.8 5.3 2.8 
Acetylfentanyl 1.7 0.7 1.8 0.7 1.4 0.7 
Butyrylfentanyl 4.6 4.9 3.0 2.2 1.5 1.9 
Carfentanil 3.1 1.2 2.9 1.2 1.7 1.9 
Fentanyl 1.6 1.2 1.5 0.9 1.0 0.6 
Furanylfentanyl 3.9 1.5 3.0 1.2 2.2 1.9 
Isobutyrylfentanyl 3.1 2.0 1.9 1.1 2.5 1.3 
Norfentanyl 7.2 3.7 2.5 1.4 0.6 2.6 
p-Fluorobutyrylfentanyl 4.4 1.8 3.5 1.5 3.8 4.1 
U-47700 5.5 2.6 2.5 1.4 4.4 2.2 
Valerylfentanyl 6.7 2.7 6.4 2.9 5.6 14.3 
 
Table 10. Summary of bias results at all three levels of QC (0.5, 8, and 80 ng/g) for 
quantitative analytes in brain (n=5) 
Analyte 
Low QC Mid QC High QC 
%Bias %Bias %Bias 
3-methylfentanyl -9.1 -6.5 6.8 
4-methoxybutyrylfentanyl -8.8 0.3 10.4 
Acetylfentanyl -2.7 -1.6 -0.4 
Butyrylfentanyl -3.2 -0.7 -0.2 
Carfentanil -7.1 3.0 0.3 
Fentanyl -5.1 -3.0 0.1 
Furanylfentanyl -5.9 -1.1 4.3 
Isobutyrylfentanyl -1.8 3.2 7.7 
Norfentanyl -3.5 -3.9 -9.3 
p-Fluorobutyrylfentanyl -6.1 0.5 5.7 
U-47700 0.1 2.2 7.4 





A majority of the analytes had matrix effects that did not exceed the 20% cut-off 
criteria for matrix effects and %CV.  Significant matrix effects were exhibited in 4-
ANPP, norfentanyl, and norfentanyl-d5 at the low QC (0.5 ng/g) and norfentanyl-d5 at the 
high QC (80 ng/g).  Although the cut-off criteria of 20% was not met for all the analytes, 
this did not have an impact on other critical validation parameters observed (LOD, LOQ, 
bias, precision) thus these observed matrix effects were considered to be not disruptive 
towards the qualitative/quantitative analysis of synthetic opioids in brain.  4-ANPP, MT-
45, norfentanyl, and norfentanyl-d5 had significantly varied matrix effects sample to 
sample as shown by the %CVs ranging from 22.2% to 43.4% in Table 11.  Since 4-ANPP 
and MT-45 were be monitored by qualitative analysis only, they were not  affected by the 
high %CV. Norfentanyl-d5 compensated well for both norfentanyl’s %CV as an internal 
standard by having similar variability per matrix thus it should not affect quantitation of 
this analyte.  Most analytes demonstrated optimal extraction efficiencies (>50%) ranging 
from 50.1% to 80.0%, except for 4-methoxybutyrylfentanyl, butyrylfentanyl, 
furanylfentanyl, MT-45, and norfentanyl which had extraction efficiencies ranging from 
21.1% to 43.4%.  However, these values appeared to be not disruptive as other critical 
validation parameters were passing as this an effect on other critical validation 
parameters observed thus the low extraction efficiencies were not considered disruptive.  
W-18 had a critically low extraction efficiency of 4.1% and 0.3% for the low and high 
QC respectively.  Due to the low extraction efficiency and the poor results obtained from 
other validation parameters, this method could not be used for quantitative or qualitative 





Table 11. Summary of matrix effect results from each analyte at the low QC (0.5 ng/g) 
and high QC (80 ng/g) in brain samples (n=10) 
Analyte 
Low QC High QC 
Matrix Effect %CV Matrix Effect %CV 
3-methylfentanyl -6.0 6.9 -2.6 2.5 
4-ANPP 25.6 43.4 10.8 23.5 
4-methoxybutyrylfentanyl -10.4 9.6 -3.0 3.5 
Acetylfentanyl -4.9 4.2 -2.9 1.4 
Butyrylfentanyl -8.1 7.9 -2.2 1.6 
Carfentanil -6.9 5.9 -3.3 2.6 
Fentanyl -6.2 4.5 -3.2 2.6 
Furanylfentanyl -6.9 6.0 -3.5 2.9 
Isobutyrylfentanyl -7.8 7.1 -2.5 2.7 
MT-45 -12.6 35.3 -9.7 10.5 
Norfentanyl -30.7 28.2 -19.9 21.1 
p-Fluorobutyrylfentanyl -9.7 8.0 -1.6 2.3 
U-47700 -13.8 7.2 -18.1 8.1 
Valerylfentanyl -15.2 16.2 -10.1 12.5 
Fentanyl-d5 -4.7 3.3 -3.2 2.4 
Norfentanyl-d5 -20.5 28.3 -20.3 22.2 
 All analytes had comparable results between fresh QC and the autosampler 
stability study, with the exceptions of 4-ANPP and U-47700.  The latter two analytes 
showed significant deterioration after 24 h on the auto-sampler at room temperature with 
percent differences greater than 40% at all three levels of QC.  Given these results, 
samples that were more than 24 h in the autosampler at room temperature cannot be re-
injected and expected to give accurate results for 4-ANPP and U-47700.  These samples 
would need to be re-extracted if it was unable to run within 24 h.  For to the remaining 
analytes, samples up to 24 h in the autosampler could be re-injected and be expected to 
give consistent results.  Injections after 48 h were not performed. 
 Most analytes were free from carryover in concentrations up to 500 ng/g.  4-
methoxybutyrylfentanyl, carfentanil, furanylfentanyl, and valerylfentanyl showed 
carryover in samples after the 500 ng/g and MT-45 showed carryover in samples after the 
29 
 
100 ng/g.  If any of the above mentioned analytes were found above 100 ng/g or 500 ng/g 
and the following sample showed the same analyte(s) present, that sample was re-injected 
to ensure carryover did not occur.   
 The quantitative analytes had acceptable low QC accuracy and ion ratios in the 
presence of exogenous interferences.  4-ANPP and MT-45 had unacceptable accuracy as 
the sample concentrations tended to be higher than expected but since these analytes were 
not quantitated, these results were acceptable.  The presence of potential endogenous 
interferences was tested by using six different sources of negative human brain tissue 
from previously tested casework. All six samples were negative for all analytes, thus no 
endogenous interferences were observed. 
 For all quantitative analytes, a dilution down to 1:2 (in addition to the 1:3 dilution 
as part of the sample preparation for brain tissue) had proven to give accurate results with 
percent differences between -18.9% to -3.7% when compared to the original 
concentration (150 ng/g).  MT-45 had a percent difference of 29.56% amongst its repeats, 
exceeding the 20% cut-off criteria.  However, due to MT-45 being tested qualitatively 
only, dilutions were not necessary.   
4.3. Case Sample Analysis 
Blood, vitreous humor, and brain samples from 58 synthetic opioid-positive 
authentic cases from 2016 were tested.  Five cases had only one synthetic opioid 
detected, whereas the remaining cases had multiple detected.  Of the synthetic opioids 
tested for in blood, vitreous humor, and brain methods, 4-ANPP, acetylfentanyl, fentanyl, 
furanylfentanyl, norfentanyl, and U-47700 were detected amongst all the case samples.  
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The most commonly detected synthetic opioid was fentanyl with 46 positive cases, and 
its two metabolites, 4-ANPP and norfentanyl, with 54 and 43 positive cases respectively. 
In six cases, an unknown peak was observed that exhibited similar characteristics 
to p-fluorobutyrylfentanyl but differed in retention time (eluting at 13.5 min compared to 
p-fluorobutyrylfentanyl at 12.9 min).  The unknown analyte had the same precursor ion, 
quantifier product ion, and qualifier product ion to p-fluorobutyrylfentanyl ion and 
exhibited similar ion ratios.   
Figure 4 shows a comparison of analyte detection amongst the tested cases, 
demonstrating how the detection of each analyte differed amongst the three matrices in 
each case.  Most analytes were detected in all three matrices in a given case.  This was 
followed by detection of an analyte in combinations of brain and another matrix or brain 
only.  4-ANPP had the highest percentage of cases in which the metabolite was only 
detected in brain (24%) as well as the highest percentage of cases in which the metabolite 
was only detected in blood and brain (22%).  Similarly to 4-ANPP, acetylfentanyl also 
showed significant variability in detectability amongst matrices with 13% of the cases 
being only detected in brain and 8% of the cases being detected in vitreous humor and 
brain.  When comparing the detection ability of each matrix, brain appears to have the 
largest percentage of detections for each analyte, with the exception of norfentanyl.  




Figure 4. Comparison of analyte detection amongst 58 tested cases in blood, vitreous 
humor, and brain. For each analyte, n represents the total number of cases that tested 
positive in at least one of the three matrices.   
Femoral blood was the preferred blood source for analysis.  However, due to the 
lack of availability of femoral blood in some cases, either cardiac, iliac or subclavian 
blood was tested instead.  Table 12 provides a summary of the concentration ranges that 
were obtained from each analyte in each matrix.  Concentration ranges were observed to 
be the highest in brain samples (with the exception of norfentanyl), followed by blood 
and vitreous humor.  A comparison of blood concentrations from different sources could 
be made but would not be significant as the sample size for the blood sources other than 






































Comparison of analyte detection amongst 58 tested 
cases in blood, vitreous humor, and brain 
% Cases tested positive all 3 matrices % Cases tested positive blood and vitreous humor
% Cases tested positive blood and brain % Cases tested positive vitreous humor and brain
% Cases tested vitreous only % Cases tested brain only
% Cases tested blood only
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Table 12. Summary of postmortem concentrations in different biological matrices for 
synthetic opioids (range, number of cases).   
The bolded concentration values were reported as a “greater than” value due to 
the detected concentration being larger than the ULOQ.  Further dilutions were attempted 
with the blood samples but the availability of sample limited how many dilutions could 
be performed therefore the ULOQ values differ.  U-47700 concentrations were observed 
to be significantly higher than the other analytes amongst all matrices.  Metabolites, 4-
ANPP and norfentanyl, were observed to be lower in concentration with the maximum 
quantified values being 45.55 ng/mL and 32.28 ng/mL in blood, respectively.   
Concentrations were further compared between matrices to see if any correlation 
could be observed.  Only femoral blood samples were analyzed in this comparison. 
Ratios were calculated between femoral blood to vitreous humor concentrations, femoral 
blood to brain concentrations, and vitreous humor to brain concentrations within the same 
Analyte 
Blood (ng/mL) Vitreous 
Humor 




(n = 24) 
15.50 - 
45.55 





(n = 3) 
0.12 - 
28.29 












(n = 12) 
0.17 - >600 




(n = 32) 
0.10 - 
9.44 
(n = 7) 
4.01 
(n = 1) 
0.52 - 
36.83 
(n = 3) 
0.19 - 
68.60 
(n = 41) 
0.34 - 
176.85 
(n = 43) 
Furanylfentanyl 
0.16 - 3.92 
(n = 7) 
7.19 - 
89.84 





(n = 3) 
0.29 - 
14.94 
(n = 16) 
0.43 - 
167.44  




(n = 29) 
0.10 - 
9.44 
(n = 7) 
3.09 
(n = 1) 
0.10 - 4.10 
(n = 3) 
0.11 - 
19.65 
(n = 34) 
0.35 - 22.10 




(n = 6) 
>500 
(n = 1) 
>100 
(n = 1) 
68.13 
(n = 1) 
0.11 - 
328.64 
(n = 9) 
1.04 - >600 
(n = 10) 
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case.  All the obtained ratios were collectively observed by analyte to see if any trends 
were present.  Table 13 shows that concentrations tended to be slightly higher in blood 
compared to vitreous humor for most analytes as the mean ratio is above 1 for all 
analytes, with the exception of furanylfentanyl, which was 0.75.  However, the range 
shows that the ratio can fall also below 1 indicating that vitreous humor concentrations 
may also be greater.  Brain samples consistently gave the highest concentration when 
compared to blood and vitreous humor for all analytes except for norfentanyl, in which 
concentrations were higher in both femoral blood and vitreous humor. 








Mean 3.71 --- --- 
Standard Deviation 4.81 --- --- 
Min-Max 0.46 - 13.53 --- --- 
n 12 --- --- 
Acetylfentanyl 
Mean 2.43 0.48 0.73 
Standard Deviation 2.19 0.28 0.70 
Min-Max 0.50 - 6.32 0.16 - 0.88 0.028 – 1.82 
n 8 8 8 
Fentanyl 
Mean 1.67 0.27 0.29 
Standard Deviation 1.42 0.17 0.26 
Min-Max 0.16 - 6.32 0.07 - 0.71 0.07 - 0.97 
n 30 32 41 
Furanylfentanyl 
Mean 0.75 0.17 0.31 
Standard Deviation 0.63 0.14 0.46 
Min-Max 0.15 - 2.04 0.02- 0.41 0.03 - 1.80 
n 7 7 14 
Norfentanyl 
Mean 5.08 2.05 1.05 
Standard Deviation 12.99 1.67 0.65 
Min-Max 0.26 - 66.59 0.09 - 8.52 0.13 - 2.72 
n 25 26 30 
U-47700 
Mean 1.94 0.40 0.19 
Standard Deviation 1.00 0.09 0.06 
Min-Max 0.59 - 3.36 0.32 - 0.51 0.11 – 0.26 





No strong correlation was observed between the different matrix concentrations 
for 4-ANPP, fentanyl, furanylfentanyl, norfentanyl, and U-47700.  Linear, exponential, 
and quadratic best-fit lines were attempted but no r2 values exceeding 0.80 were 
attainable, except for acetylfentanyl.  Moderate linear correlation was observed in 
acetylfentanyl concentration ratios when comparing vitreous humor versus femoral blood 
concentrations (Figure 5) and brain versus femoral blood concentrations (Figure 6) as the 
r2 values for the best-fit lines were above 0.85.   No correlation was observed between 
brain versus vitreous humor concentrations, with an r2 value of zero (Figure 7). 
Figure 5. Plot of acetylfentanyl concentrations in brain versus femoral blood (n= 8) 
 







































Figure 6. Plot of acetylfentanyl concentrations in vitreous humor versus femoral blood 
(n= 8) 
 
Figure 7. Plot of acetylfentanyl concentrations in brain versus vitreous humor (n= 8) 
 Figures 8 through 10 show total ion chromatograms (TIC) obtained from different 
matrix samples from the same case.  It was observed that norfentanyl, acetylfentanyl, 4-
ANPP and fentanyl were detected across all matrices.  This trend was commonly seen 
across a majority of the cases were the same analyte was detected in all three matrices.  





























Acetylfentanyl: [Brn] vs [Fem Bld]




























Acetylfentanyl: [Brn] vs [Vit]
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However, some exceptions did exist where analytes were only detected in one or two 
matrices (refer to Figure 4), especially in cases with acetylfentanyl, where only 39% of 
the 54 cases tested were detected across all three matrices.   
Figure 8. Total ion chromatogram (TIC) of femoral blood specimen from case FT16-
00981.  Norfentanyl (0.40 ng/mL), acetylfentanyl (0.56 ng/mL), 4-ANPP (0.15 ng/mL), 










Figure 9. Total ion chromatogram (TIC) of vitreous humor specimen from case FT16-
00981.  Norfentanyl (0.45 ng/mL), acetylfentanyl (0.67 ng/mL), 4-ANPP (detected), and 
fentanyl (8.21 ng/mL) were detected.  4-ANPP was detected but could not be quantitated 
due to being below the LOQ (0.1 ng/mL). 
Figure 10. Total ion chromatogram (TIC) of brain specimen from case FT16-00981.  
Norfentanyl (0.46 ng/g), acetylfentanyl (0.85 ng/g), 4-ANPP (detected), and fentanyl 






There have been a number of methods previously published on the detection of 
new synthetic opioids in blood (Mochizuki, Nakazawa, Adachi, Takekawa, and Shojo, 
2018; Seither and Reidy, 2017; Mohr et al., 2016; Clavijo et al., 2011) and only a few 
publications available in alternative postmortem matrices like vitreous humor and brain 
(Sofalvi et al., 2017; Poklis et al., 2016; Poklis et al., 2015).   This is the first known 
method to incorporate 13 synthetic opioids in vitreous humor and 12 synthetic opioids in 
brain for quantification by LC-MSMS.   
The method for quantifying synthetic opioids in vitreous humor was cross-
validated with the blood method obtained from the NYC-OCME with no significant 
changes needed to the original method.  The same extraction procedure used in the blood 
method was applied to vitreous humor samples and produced acceptable results through 
validation.  The method for quantifying synthetic opioids in brain required optimization 
in its extraction procedure in order to obtain a cleaner extract.  The initial extraction 
method tested was the same extraction method used for blood and vitreous humor 
samples without a methanol wash in the SPE procedure.  Although the initial extraction 
method tested provided sufficient results at first glance, it was not practical to use 
routinely on an instrument due to the fatty extracts produced by the brain specimens.  
Brain, being highly lipophilic, needed an additional wash step to incorporate into the 
procedure (Chang, Ke, and Chen, 2009).  Different organic solvents and diluted methanol 
solutions were tested in triplicate to compare the extraction efficiency of each.  The 
incorporation of an additional methanol wash as the third wash step exhibited the best 
extraction efficiency for a majority of the analytes, with the exception of norfentanyl and 
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its internal standard.  Norfentanyl and norfentanyl-d5 demonstrated significantly lower 
extraction efficiencies compared to the results obtained without the additional wash step.  
However, due to the effectiveness of this methanol wash step with the remaining analytes 
and being that norfentanyl and norfentanyl-d5 were able to pass the necessary validation 
requirements with the methanol wash step addition, the lower extraction efficiencies 
(<50%) were not of major concern and the method was deemed acceptable to use for the 
purpose of this study. 
Concentration ranges for all the synthetic opioid parent drugs (acetylfentanyl, 
fentanyl, furanylfentanyl, U-47700) were compared to concentrations detected in 
previously published case studies.  Concentration ranges obtained for acetylfentanyl and 
fentanyl were very large, with concentrations as low as the LLOQ (0.1 ng/mL) and 
concentrations greater than the ULOQ (100 ng/mL).  Case studies have shown similar 
characteristics in femoral blood for acetylfentanyl, with ranges from 16 to 600 ng/mL 
(Cunningham, Haikal, and Kraner, 2016; Dwyer, Janssen, Luckasevic, and Williams, 
2018; Fort et al., 2016; McIntyre, Trochta, Gary, Malamatos, and Lucas, 2015; Pearson et 
al., 2015; Poklis et al., 2015; Takase, Koizumi, Fujimoto, Yanai, and Fujimiya, 2016; 
Yonemitsu, Sasao, Mishima, Ohtsu, and Nishitani, 2016).  However, most fentanyl case 
studies have detected concentrations within the 0.1 to 100 ng/mL range (up to 60 ng/mL) 
in femoral blood (Anderson and Muto, 2000; Bakovic, Nestic, and Mayer, 2015; 
Biedrzycki, Bevan, and Lucas, 2009; Carson et al., 2010; Coopman et al., 2007; Dwyer et 
al., 2018; Krinsky, Lathrop, Crossey, Baker, and Zumwalt, 2011; Krinsky, Lathrop, and 
Zumwalt, 2014; Kuhlman, McCaulley, Valouch, and Behonick, 2003; Marinetti and 
Ehlers, 2014; Martin, Woodall, and McLellan, 2006; McIntyre, Gary, and Estrada, 2014; 
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Moore, Palmer, and Donovan, 2015; Palamalai et al., 2013; Pearson et al., 2015; Poklis et 
al., 2015; Rodda et al., 2017).  Furanylfentanyl had a very low concentration range in 
femoral blood (0.16-3.92 ng/mL) compared to vitreous humor (0.29-14.94 ng/mL) and 
brain tissue (0.43-167.44 ng/g) in cases where detected.  However, these results showed 
consistency with case studies by Guerrieri, Rapp, Roman, Druid, and Kronstrand (2017) 
and Martucci et al. (2017), which focused on postmortem cases where furanylfentanyl 
was detected.  In these studies, the concentrations detected ranged from 0.4 to 2.89 
ng/mL in femoral blood and detected below the LOQ (0.2 ng/mL) in vitreous humor.   
Limited case studies were available for comparison of vitreous humor and brain 
concentrations.  Two case studies observed vitreous humor concentrations for 
acetylfentanyl, reporting concentrations of 140 ng/mL and 240 ng/mL (Fort et al., 2016; 
McIntyre et al., 2015).  One case study observed brain concentrations for acetylfentanyl 
reported as 620 ng/g (Fort et al., 2016).  Four case studies observed vitreous humor 
concentrations for fentanyl, reporting concentrations ranging from 8 ng/mL to 20 ng/mL 
(Coopman et al., 2007; Anderson et al., 2000).   
U-47700 had a significantly higher concentration range throughout all three 
matrices when compared to the other analytes detected.  Case samples that detected U-
47700 often required dilutions due to being over the ULOQ, which was 100 ng/mL for all 
methods.  Other case reports (McIntyre, Cary, Joseph, and Stabley, 2017; Ellefsen, 
Taylor, Simmons, Willoughby, and Hall, 2017; Dziadosz et al., 2017) have reported fatal 
concentrations of U-47700 over 100 ng/mL in femoral blood, vitreous humor, and brain, 
consistent with the high concentrations obtained from this study.  U-47700, although still 
present in lower concentrations (<100 ng/mL), appears to have a lower potency relative 
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to fentanyl and the other synthetic opioids that were detected in this study shown by the 
large “fatal” concentrations associated with this substance. 
It was observed that all analytes detected had their highest concentrations 
observed in brain tissue with the exception of norfentanyl.  Case studies involving 
acetylfentanyl and fentanyl, where blood and brain tissue from the same case were tested, 
showed similar trends with brain concentrations being significantly higher than blood 
concentrations regardless the source (Fort et al., 2016).  In a study by Rohrig and Hicks 
(2015), femoral flood and heart blood concentrations in various common drugs of abuse 
(including fentanyl) were compared to concentrations in brain tissue.  Their results for 
femoral blood and brain tissue comparisons were consistent with the results obtained for 
fentanyl in this study, showing a low mean femoral blood-to-brain concentration ratio of 
0.28 and a range of 0.027 to 0.77.   Two case studies involving U-47700 found brain 
concentrations to be consistently lower than femoral blood concentrations, opposing the 
results obtained from this study (Rohrig et al., 2018; Dziadosz et al., 2017).   
In most cases, detected analytes were detectable across all three matrices, with the 
exception of 4-ANPP which appeared to have a higher affinity towards brain tissue (see 
Figure 4).  In the few cases where an analyte was present and unable to be detected in 
blood, the analyte was usually detected in brain tissue, with the exception of norfentanyl, 
showing a lower affinity for brain tissue. All samples were known to have been collected 
by the medical examiner within two days of the date of death.  However, the survival 
times of the individuals were unknown, which would have allowed for further 
interpretation of the obtained results from these cases.  The concentrations tended to be 
higher in brain in most cases or had slightly higher detectability in the brain compared to 
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blood and vitreous humor.  This was most likely due to the physiochemical properties of 
the drugs and their lipophilicity affecting its ability to cross the blood-brain barrier. The 
more lipophilic a substance is, the higher its ability to penetrate the blood-brain barrier. 
However, without knowing how far along the individual was administered substance 
prior to death, it is difficult to determine if the distribution of the analytes amongst 
different matrices was also due to other factors, such as postmortem redistribution or the 
time of death or both.  This study looks at the distribution of the analytes without 
considering survival time, but further research is recommended to incorporate this 
variable to allow for further interpretation 
When comparing the concentrations detected in each case between the three 
matrices, it was observed that concentrations detected from vitreous humor and brain 
could not be reliably traced back to an individual’s blood concentration based on prior 
observations.  There were no strong correlations observed between the concentrations of 
any two matrices for most of the analytes.  This exception being acetylfentanyl, which 
showed some correlation especially between femoral blood and brain concentrations 
(refer to Figures 5 through 7).  However, due to the small sample size of cases (n=8-9), a 
larger sample size is recommended to determine if the correlation between acetylfentanyl 
concentrations between matrices is significant on a large scale. 
Amongst all the 2016 cases that were retested, only six different analytes were 
detected: 4-ANPP, acetylfentanyl, fentanyl, furanylfentanyl, norfentanyl, and U-47700.  
None of the new synthetic opioids that were incorporated in this method (3-
methylfentanyl, 4-methoxybutyrylfentanyl, butyrylfentanyl, carfentanil, 
isobutyrylfentanyl, MT-45, valerylfentanyl, and W-18) were detected in the case samples.  
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Based on the Annual 2016 Emerging Threat Report curated by the Drug Enforcement 
Administration (DEA), the synthetic opioids detected amongst these cases are consistent 
with the top five opioids seized in the United States over the year of 2016.  Fentanyl was 
the most commonly seen, followed by furanylfentanyl, acetylfentanyl, U-47700, and 4-
ANPP (DEA, 2016).  The synthetic opioids detected in this study were mostly fentanyl 
and 4-ANPP, followed by acetylfentanyl, furanylfentanyl, and U-47700.  4-ANPP exists 
as is a metabolite to fentanyl and furanylfentanyl and a drug precursor, thus the number 
of cases where 4-ANPP was detected were most abundant.  Other drugs incorporated in 
the developed method were also listed in the Emerging Threat Report, including 
carfentanil, acrylfentanyl, butyrylfentanyl, valerylfentanyl, p-fluorobutyrylfentanyl, and 
3-methylfentanyl, but were not detected in any of the 58 cases analyzed. 
In addition to the six detected analytes, an unknown peak was also detected but 
could not be identified in six of 58 cases that were tested.  The unknown peak was most 
prevalent in the brain samples, as not all blood and vitreous humor samples for the same 
cases exhibited these peaks.  It is expected that this unknown analyte is similar in 
composition and chemical structure to p-fluorobutyrylfentanyl due to the results obtained 
from the programmed MRM LC-MSMS method.  The program detected this analyte as p-
fluorobutyrylfentanyl, but the possibility was eliminated due to not having a passing 
retention time.  An ongoing project at the NYC-OCME had focused on identifying an 
unknown peak present in 2017 casework, similar to the one observed in these cases 
tested.  This project was able to identify the unknown peak in the 2017 casework as p-
fluoroisobutyrylfentanyl, an isomer of p-fluorobutyrylfentanyl.  It is probable that the 
unknown peak present in these tested 2016 cases also will identify as p-
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fluoroisobutyrylfentanyl.  However, additional testing would be necessary to confirm this 
observation.  
5. Conclusion 
Methods were developed and validated for the quantification of 13 synthetic 
opioids in vitreous humor and the quantification of 12 synthetic opioids in brain.  MT-45 
and W-18 were considered qualitative only for vitreous humor and 4-ANPP and MT-45 
were considered qualitative only for brain samples.  W-18 could not be reliably detected 
in brain samples.  The synthetic opioids displayed a higher affinity for brain tissue when 
compared to blood and vitreous humor as presented by the larger concentrations detected 
in the brain samples, except for norfentanyl.  Brain tissue and vitreous humor were 
demonstrated to be effective alternatives in detecting the presence of synthetic opioids in 
place of blood.  However, no correlation between the matrices can be made with the 
concentrations detected.   
By developing and validating quantitative methods in alternative matrices, more 
options were introduced when analyzing postmortem cases that involve synthetic opioid 
use.  In cases where blood is sparse or no synthetic opioid(s) are detected, understanding 
synthetic opioids in a postmortem setting is essential when attempting to rule out the 
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Summary of results obtained from retested 2016 cases for synthetic opioids  
The following table represents the results obtained from the 58 cases that were tested in 
this study, with the analytes detected and the corresponding concentrations in each 
matrix.  All cases involved multiple substance use and was not limited to synthetic 
opioids.  The manner and cause of death were accidental and overdose related deaths 














FT16-00577 U-47700 >600 160.14 356.79 Femoral  
FT16-00776 





Acetylfentanyl 0.17 Detected Not detected 
Furanylfentanyl 122.02 3.85 14.8 
U-47700 >600 257.91 >100 
FT16-00850 





Acetylfentanyl 1.58 2.88 0.45 
Fentanyl 20.07 13.08 4.01 
Norfentanyl 1.10 1.97 3.09 
FT16-00952 
4-ANPP Detected 0.12 0.28 
Femoral   
Acetylfentanyl 26.71 12.20 8.31 
Fentanyl 134.20 60.65 44.74 
Norfentanyl 4.55 12.35 7.13 
FT16-00981 
4-ANPP Detected Detected 0.15 
Femoral   
Acetylfentanyl 0.85 0.67 0.56 
Fentanyl 17.61 8.21 9.81 
Norfentanyl 0.46 0.45 0.40 
FT16-01014 
4-ANPP Detected 0.76 5.61 
Heart   Fentanyl 118.02 6.74 82.9 
U-47700 528.36 59.17 >500 
FT16-01189 
4-ANPP Detected Not detected Detected 
Femoral   Acetylfentanyl 1101.21 45.21 227.15 
Fentanyl Detected Not detected Not detected 
FT16-01731 
4-ANPP Detected 6.52 9.05 
Femoral   
Acetylfentanyl 9.50 15.87 7.94 
Fentanyl 58.48 3.29 52.52 
Furanylfentanyl 1.82 3.28 0.74 

















4-ANPP Detected Not detected Not detected 
Femoral   
Acetylfentanyl 95.66 2.69 16.99 
Fentanyl 104.07 3.29 20.66 
Norfentanyl 1.01 0.13 8.61 
FT16-02134 
4-ANPP Detected Not detected 0.13 
Femoral   
Acetylfentanyl 9.90 0.96 2.88 
Fentanyl 67.21 5.12 16.55 
Norfentanyl 1.67 1.10 3.76 
FT16-02205 
4-ANPP Detected Not detected Not detected 
Femoral   Fentanyl 15.98 1.30 5.98 
Norfentanyl 1.09 0.48 1.49 
FT16-02216 
4-ANPP Detected 1.41 Not detected 
Heart   
Furanylfentanyl 45.53 2.27 7.19 
FT16-02220 
4-ANPP Detected Not detected 19.08 
Femoral   Fentanyl 75.45 17.00 17.46 
Norfentanyl 2.17 2.20 Not detected 
FT16-02221 4-ANPP Detected Not detected Not detected Femoral   
FT16-02226 
4-ANPP Detected Not detected Not detected 
Femoral   
Fentanyl 12.88 Detected 0.10 
FT16-02228 
4-ANPP Detected Not detected Not detected 
Femoral   Fentanyl 3.55 1.58 3.87 
Norfentanyl 0.76 0.28 1.12 
FT16-02236 4-ANPP Detected 0.19 0.15 Heart   
FT16-02238 
4-ANPP Detected Not detected Not detected 
Heart   
Acetylfentanyl Detected Detected Detected 
Fentanyl 61.22 8.18 9.44 
Norfentanyl 0.46 0.13 0.65 
FT16-02251 
4-ANPP Detected 0.28 0.61 
Femoral   Fentanyl 38.01 9.48 12.64 
Norfentanyl 0.57 0.17 0.45 
FT16-02252 
4-ANPP Detected Not detected Not detected 
Heart   Fentanyl 0.39 0.51 0.16 
Norfentanyl 1.07 2.17 2.06 
FT16-02264 





Fentanyl 13.97 4.69 3.43 
Norfentanyl 1.81 3.66 3.76 
FT16-02272 
4-ANPP Detected 3.15 6.53 
Femoral   

















4-ANPP Detected Detected Not detected 
Femoral   
Fentanyl 50.11 8.76 1.22 
Norfentanyl Detected Not detected 0.22 
U-47700 >600 230.99 135.63 
FT16-02305 Fentanyl 2.12 0.19 0.68 Heart 
Case consisted 
of a motor 
vehicle accident Norfentanyl Not detected Not detected 0.28 
FT16-02317 
4-ANPP Detected 0.22 1.14 
Femoral   Fentanyl 39.82 10.21 22.46 
Norfentanyl 1.37 1.57 3.20 
FT16-02320 
4-ANPP Detected Detected 0.28 
Femoral   
Acetylfentanyl Not detected Not detected Detected 
Fentanyl 53.36 11.61 37.84 
Norfentanyl 4.82 1.98 15.35 
FT16-02322 
4-ANPP Not detected 0.32 Detected 
Femoral   Fentanyl 1.48 3.87 0.56 
Norfentanyl Not detected 3.03 1.50 
FT16-02324 
4-ANPP Detected 1.10 2.93 
Femoral   
Furanylfentanyl 14.01 1.17 0.64 
FT16-02332 U-47700 1.14 Not detected Not detected Heart   
FT16-02346 
4-ANPP Not detected Detected 0.33 
Femoral   Fentanyl 57.57 22.33 30.44 
Norfentanyl 2.04 2.04 10.07 
FT16-02349 
4-ANPP Not detected 3.03 2.59 
Femoral   
Fentanyl Not detected Detected Detected 
Furanylfentanyl 0.43 0.36 Detected 
Norfentanyl Not detected 0.11 Not detected 
FT16-02352 
4-ANPP Detected Not detected 2.59 
Femoral   
Acetylfentanyl 0.22 Detected Detected 
Fentanyl 84.55 16.00 20.37 
Norfentanyl 1.26 1.58 2.08 
FT16-02357 
4-ANPP Detected Detected Detected 
Femoral   
Acetylfentanyl Not detected 0.13 Not detected 
Fentanyl 41.27 16.05 6.05 
Norfentanyl 3.42 4.54 2.54 
FT16-02372 
4-ANPP Detected Not detected Not detected 
Femoral   
Acetylfentanyl Detected Not detected Detected 
Fentanyl 74.00 9.19 12.19 

















4-ANPP Detected Not detected 0.17 
Femoral   
Acetylfentanyl 0.34 Detected 0.10 
Fentanyl 121.93 14.20 32.05 
Norfentanyl 0.96 0.28 2.42 
FT16-02377 
4-ANPP Detected Not detected Not detected 
Femoral   Fentanyl 34.59 8.14 3.84 
Norfentanyl 0.46 0.29 0.78 
FT16-02388 
4-ANPP Detected Not detected Not detected 
Heart 
Manner of death 
was deemed 
suicide 
Fentanyl 4.42 0.77 0.75 
Norfentanyl Detected Detected 0.81 
FT16-02390 
4-ANPP Detected Not detected Not detected 
Femoral   Fentanyl Detected Detected Detected 
Norfentanyl Not detected Not detected Detected 
FT16-02394 
4-ANPP Detected Not detected Detected 
Heart   
Fentanyl 20.96 1.38 7.31 
Furanylfentanyl Detected Not detected Not detected 
Norfentanyl Not detected Not detected 0.17 
FT16-02403 
4-ANPP Detected Not detected 0.14 
Femoral   
Acetylfentanyl 0.3 Not detected Detected 
Fentanyl 160.67 10.7 37.44 
Norfentanyl 4.85 6.60 9.82 
FT16-02408 
4-ANPP Detected Not detected Detected 
Femoral   Fentanyl 35.87 11.41 15.01 
Norfentanyl 22.10 14.04 38.28 
FT16-02409 





Acetylfentanyl 0.28 Detected Not detected 
Fentanyl 95.55 13.31 7.03 
Norfentanyl 0.56 0.88 0.23 
FT16-02417 




Acetylfentanyl 44.22 6.13 12.77 
Fentanyl 138.55 17.72 97.91 
Norfentanyl 3.11 Detected 0.27 
FT16-02418 
4-ANPP Detected Not detected Not detected 
Femoral   Fentanyl 26.03 3.09 6.92 
Norfentanyl Detected Not detected 0.62 
FT16-02445 
4-ANPP Detected 0.13 Not detected 
Femoral   
Acetylfentanyl Detected 0.17 Detected 
Fentanyl 176.85 68.60 26.82 

















4-ANPP Detected 0.96 4.38 
Femoral   Furanylfentanyl 42.94 5.54 0.83 
U-47700 102.1 18.58 32.92 
FT16-02836 
4-ANPP Not detected 0.38 0.17 
Femoral   
Acetylfentanyl Detected Not detected Not detected 
Fentanyl 104.01 21.49 14.92 
Norfentanyl 2.17 2.30 3.44 
U-47700 1.04 0.11 0.40 
FT16-02926 
4-ANPP Detected 13.25 11.72 
Subclavian   
Acetylfentanyl Detected 0.41 0.12 
Fentanyl 1.02 0.99 0.52 
Furanylfentanyl 167.44 14.94 47.21 
Norfentanyl Not detected 0.12 0.10 
FT16-02929 
4-ANPP Detected 2.01 3.93 
Subclavian   
Acetylfentanyl 0.32 Not detected 0.12 
Fentanyl 150.22 14.55 36.83 
Furanylfentanyl 1.52 0.88 0.85 
Norfentanyl 1.84 0.97 4.10 
FT16-02930 
4-ANPP Detected 0.34 1.49 
Femoral   
Acetylfentanyl 0.34 Detected Detected 
Fentanyl 83.85 12.63 19.74 
Furanylfentanyl 0.68 0.29 0.16 
Norfentanyl 0.81 0.70 0.76 
U-47700 19.01 4.95 9.62 
FT16-02980 
4-ANPP Detected 1.31 17.73 
Femoral   Fentanyl 0.34 Detected 0.10 
Furanylfentanyl 26.51 1.83 3.73 
FT16-03017 
4-ANPP Detected Not detected 0.47 
Femoral   
Acetylfentanyl 0.29 Detected Detected 
Fentanyl 67.20 21.22 33.13 
Norfentanyl 2.73 4.36 8.45 
FT16-03056 
4-ANPP Detected Detected 0.16 
Femoral   
Acetylfentanyl 0.73 0.63 0.64 
Fentanyl 116.85 20.74 33.79 
Norfentanyl 2.65 1.64 3.87 
FT16-03068 
4-ANPP Detected 4.22 17.59 
Heart   
Fentanyl 1.35 1.24 0.87 
Furanylfentanyl 80.21 7.56 12.09 

















4-ANPP Detected 4.96 45.55 
Heart   
Fentanyl 1.83 0.78 1.93 
Furanylfentanyl 57.29 7.59 89.84 
Norfentanyl Not detected 0.13 0.39 
FT16-03190 
4-ANPP Not detected 1.63 8.07 
Femoral   
Furanylfentanyl 45.36 4.51 3.92 
FT16-03365 
4-ANPP Detected 3.63 0.34 
Subclavian   
Fentanyl 5.18 3.21 2.55 
Furanylfentanyl 44.23 8.58 3.48 
Norfentanyl 0.37 0.59 0.64 
U-47700 25.7 127.49 68.13 
FT16-03499 U-47700 >600 328.64 492.84 Femoral   
 
 
